Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL

NCT05918276 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

CLL/SLL

Interventions

DRUG: Orelabrutinib and BG

Sponsor

Nanfang Hospital, Southern Medical University